CAS NO: | 2749281-71-6 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4receptor agonist. NUCC-390 dihydrochloride induces internalization ofCXCR4receptors and acts in an opposite way of AMD3100 (HY-10046)[1]. NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo[2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | NUCC-390 dihydrochloride (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100[1].NUCC-390 dihydrochloride (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors[1].NUCC-390 dihydrochloride (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1].NUCC-390 dihydrochloride (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. Western Blot Analysis[1]
Cell Proliferation Assay[2]
| ||||||||||||||||
体内研究 (In Vivo) | NUCC-390 dihydrochloride (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2].
| ||||||||||||||||
分子量 | 468.46 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C23H35Cl2N5O | ||||||||||||||||
CAS 号 | 2749281-71-6 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(213.47 mM;Need ultrasonic) H2O : 25 mg/mL(53.37 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|